595 related articles for article (PubMed ID: 29922291)
1. Transcriptomics of the Vaccine Immune Response: Priming With Adjuvant Modulates Recall Innate Responses After Boosting.
Santoro F; Pettini E; Kazmin D; Ciabattini A; Fiorino F; Gilfillan GD; Evenroed IM; Andersen P; Pozzi G; Medaglini D
Front Immunol; 2018; 9():1248. PubMed ID: 29922291
[TBL] [Abstract][Full Text] [Related]
2. Intrapulmonary (i.pulmon.) Pull Immunization With the Tuberculosis Subunit Vaccine Candidate H56/CAF01 After Intramuscular (i.m.) Priming Elicits a Distinct Innate Myeloid Response and Activation of Antigen-Presenting Cells Than i.m. or i.pulmon. Prime Immunization Alone.
Thakur A; Pinto FE; Hansen HS; Andersen P; Christensen D; Janfelt C; Foged C
Front Immunol; 2020; 11():803. PubMed ID: 32457748
[TBL] [Abstract][Full Text] [Related]
3. Heterologous Prime-Boost Combinations Highlight the Crucial Role of Adjuvant in Priming the Immune System.
Ciabattini A; Pettini E; Fiorino F; Lucchesi S; Pastore G; Brunetti J; Santoro F; Andersen P; Bracci L; Pozzi G; Medaglini D
Front Immunol; 2018; 9():380. PubMed ID: 29593710
[TBL] [Abstract][Full Text] [Related]
4. Immunological and physical evaluation of the multistage tuberculosis subunit vaccine candidate H56/CAF01 formulated as a spray-dried powder.
Thakur A; Ingvarsson PT; Schmidt ST; Rose F; Andersen P; Christensen D; Foged C
Vaccine; 2018 May; 36(23):3331-3339. PubMed ID: 29699790
[TBL] [Abstract][Full Text] [Related]
5. Peptide-specific T helper cells identified by MHC class II tetramers differentiate into several subtypes upon immunization with CAF01 adjuvanted H56 tuberculosis vaccine formulation.
Prota G; Christensen D; Andersen P; Medaglini D; Ciabattini A
Vaccine; 2015 Nov; 33(48):6823-30. PubMed ID: 26494626
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the Antigen-Specific CD4(+) T Cell Response Induced by Prime-Boost Strategies with CAF01 and CpG Adjuvants Administered by the Intranasal and Subcutaneous Routes.
Ciabattini A; Prota G; Christensen D; Andersen P; Pozzi G; Medaglini D
Front Immunol; 2015; 6():430. PubMed ID: 26379666
[TBL] [Abstract][Full Text] [Related]
7. Dual-Isotope SPECT/CT Imaging of the Tuberculosis Subunit Vaccine H56/CAF01: Induction of Strong Systemic and Mucosal IgA and T-Cell Responses in Mice Upon Subcutaneous Prime and Intrapulmonary Boost Immunization.
Thakur A; Rodríguez-Rodríguez C; Saatchi K; Rose F; Esposito T; Nosrati Z; Andersen P; Christensen D; Häfeli UO; Foged C
Front Immunol; 2018; 9():2825. PubMed ID: 30555488
[TBL] [Abstract][Full Text] [Related]
8. Toll like-receptor agonist Pam
Kennerknecht K; Noschka R; Löffler F; Wehrstedt S; Pedersen GK; Mayer D; Grieshober M; Christensen D; Stenger S
Med Microbiol Immunol; 2020 Apr; 209(2):163-176. PubMed ID: 32020284
[TBL] [Abstract][Full Text] [Related]
9. Pulmonary Administration of the Liposome-Based Adjuvant CAF01: Effect of Surface Charge on Mucosal Adjuvant Function.
Müllertz OAO; Andersen P; Christensen D; Foged C; Thakur A
Mol Pharm; 2023 Feb; 20(2):953-970. PubMed ID: 36583936
[TBL] [Abstract][Full Text] [Related]
10. Modulation of Primary Immune Response by Different Vaccine Adjuvants.
Ciabattini A; Pettini E; Fiorino F; Pastore G; Andersen P; Pozzi G; Medaglini D
Front Immunol; 2016; 7():427. PubMed ID: 27781036
[TBL] [Abstract][Full Text] [Related]
11. Parenteral Vaccination With a Tuberculosis Subunit Vaccine in Presence of Retinoic Acid Provides Early but Transient Protection to
Riccomi A; Piccaro G; Christensen D; Palma C; Andersen P; Vendetti S
Front Immunol; 2019; 10():934. PubMed ID: 31130946
[TBL] [Abstract][Full Text] [Related]
12. Optimize Prime/Boost Vaccine Strategies: Trained Immunity as a New Player in the Game.
Palgen JL; Feraoun Y; Dzangué-Tchoupou G; Joly C; Martinon F; Le Grand R; Beignon AS
Front Immunol; 2021; 12():612747. PubMed ID: 33763063
[TBL] [Abstract][Full Text] [Related]
13. Systematic Evaluation of Kinetics and Distribution of Muscle and Lymph Node Activation Measured by
Win Z; Weiner Rd J; Listanco A; Patel N; Sharma R; Greenwood A; Maertzdorf J; Mollenkopf HJ; Pizzoferro K; Cole T; Bodinham CL; Kaufmann SHE; Denoel P; Del Giudice G; Lewis DJM
Front Immunol; 2020; 11():613496. PubMed ID: 33613536
[TBL] [Abstract][Full Text] [Related]
14. Routing dependent immune responses after experimental R848-adjuvated vaccination.
van Aalst S; Jansen MAA; Ludwig IS; van der Zee R; van Eden W; Broere F
Vaccine; 2018 Mar; 36(11):1405-1413. PubMed ID: 29409680
[TBL] [Abstract][Full Text] [Related]
15. Mucosal boosting of H56:CAF01 immunization promotes lung-localized T cells and an accelerated pulmonary response to Mycobacterium tuberculosis infection without enhancing vaccine protection.
Woodworth JS; Christensen D; Cassidy JP; Agger EM; Mortensen R; Andersen P
Mucosal Immunol; 2019 May; 12(3):816-826. PubMed ID: 30760832
[TBL] [Abstract][Full Text] [Related]
16. A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human.
van Dissel JT; Joosten SA; Hoff ST; Soonawala D; Prins C; Hokey DA; O'Dee DM; Graves A; Thierry-Carstensen B; Andreasen LV; Ruhwald M; de Visser AW; Agger EM; Ottenhoff TH; Kromann I; Andersen P
Vaccine; 2014 Dec; 32(52):7098-107. PubMed ID: 25454872
[TBL] [Abstract][Full Text] [Related]
17. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.
Leroux-Roels I; Roman F; Forgus S; Maes C; De Boever F; Dramé M; Gillard P; van der Most R; Van Mechelen M; Hanon E; Leroux-Roels G
Vaccine; 2010 Jan; 28(3):849-57. PubMed ID: 19835828
[TBL] [Abstract][Full Text] [Related]
18. Development and preclinical safety evaluation of a new therapeutic HIV-1 vaccine based on 18 T-cell minimal epitope peptides applying a novel cationic adjuvant CAF01.
Fomsgaard A; Karlsson I; Gram G; Schou C; Tang S; Bang P; Kromann I; Andersen P; Andreasen LV
Vaccine; 2011 Sep; 29(40):7067-74. PubMed ID: 21767590
[TBL] [Abstract][Full Text] [Related]
19. Self-adjuvanted mRNA vaccines induce local innate immune responses that lead to a potent and boostable adaptive immunity.
Kowalczyk A; Doener F; Zanzinger K; Noth J; Baumhof P; Fotin-Mleczek M; Heidenreich R
Vaccine; 2016 Jul; 34(33):3882-93. PubMed ID: 27269061
[TBL] [Abstract][Full Text] [Related]
20. Improved CD4⁺ T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: a randomized trial.
Leroux-Roels I; Forgus S; De Boever F; Clement F; Demoitié MA; Mettens P; Moris P; Ledent E; Leroux-Roels G; Ofori-Anyinam O;
Vaccine; 2013 Apr; 31(17):2196-206. PubMed ID: 22643213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
